Tumor size at the time of adoptive transfer determines whether tumor rejection occurs - PubMed (original) (raw)
Comparative Study
Tumor size at the time of adoptive transfer determines whether tumor rejection occurs
T A Cordaro et al. Eur J Immunol. 2000 May.
Free article
Abstract
Here we investigate the minimal requirements for induction of an anti-tumor response in CD8 T cells in vivo. We compare the efficacy of adoptive transfer of CD8 T cells with a transgenic TCR specific for the main cytotoxic T lymphocyte epitope of the influenza virus nucleoprotein (NP) on the growth of NP-expressing EL4 tumors under different conditions. In a setting in which tumor rejection is solely dependent on tumor-specific CD8 T cells, small immunogenic tumors fail to induce a rejection response, despite the fact that they are not ignored: tumor-specific CD8 T cells are activated, differentiate into effector cells and infiltrate the tumor bed. Nevertheless, tumor rejection does not occur. In sharp contrast, the same immunogenic tumor, when growing as a large tumor mass, is rejected by transferred tumor-specific CD8 T cells. The main features which distinguish the rejection response to a large tumor mass from the response to a small tumor is that, in the latter case, activated CD8 T cells appear much later, and in much smaller numbers. Efficacy of adoptive transfer is thus dictated by the size of the tumor mass at the time of transfer. These findings predict that treatment of minimal residual disease with adoptive transfer will fail, unless vaccination is also provided at the time of transfer.
Similar articles
- Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
Prévost-Blondel A, Zimmermann C, Stemmer C, Kulmburg P, Rosenthal FM, Pircher H. Prévost-Blondel A, et al. J Immunol. 1998 Sep 1;161(5):2187-94. J Immunol. 1998. PMID: 9725210 - Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
Janicki CN, Jenkinson SR, Williams NA, Morgan DJ. Janicki CN, et al. Cancer Res. 2008 Apr 15;68(8):2993-3000. doi: 10.1158/0008-5472.CAN-07-5008. Cancer Res. 2008. PMID: 18413769 - Visualizing the course of antigen-specific CD8 and CD4 T cell responses to a growing tumor.
Klein L, Trautman L, Psarras S, Schnell S, Siermann A, Liblau R, von Boehmer H, Khazaie K. Klein L, et al. Eur J Immunol. 2003 Mar;33(3):806-14. doi: 10.1002/eji.200323800. Eur J Immunol. 2003. PMID: 12616501 - Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
Manning TC, Rund LA, Gruber MM, Fallarino F, Gajewski TF, Kranz DM. Manning TC, et al. J Immunol. 1997 Nov 15;159(10):4665-75. J Immunol. 1997. PMID: 9366389 - Initial TCR transgenic precursor frequency alters functional behaviour of CD8 T cells responding to acute infection.
Wirth T, Harty JT. Wirth T, et al. Adv Exp Med Biol. 2009;633:71-80. doi: 10.1007/978-0-387-79311-5_7. Adv Exp Med Biol. 2009. PMID: 19209682 Review. No abstract available.
Cited by
- Drugs and Clinical Approaches Targeting the Antiapoptotic Protein: A Review.
Han Z, Liang J, Li Y, He J. Han Z, et al. Biomed Res Int. 2019 Sep 29;2019:1212369. doi: 10.1155/2019/1212369. eCollection 2019. Biomed Res Int. 2019. PMID: 31662966 Free PMC article. Review. - Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances.
Simpson GR, Relph K, Harrington K, Melcher A, Pandha H. Simpson GR, et al. Oncolytic Virother. 2016 Jan 6;5:1-13. doi: 10.2147/OV.S66083. eCollection 2016. Oncolytic Virother. 2016. PMID: 27579292 Free PMC article. Review. - Challenges and future perspectives of T cell immunotherapy in cancer.
de Aquino MT, Malhotra A, Mishra MK, Shanker A. de Aquino MT, et al. Immunol Lett. 2015 Aug;166(2):117-33. doi: 10.1016/j.imlet.2015.05.018. Epub 2015 Jun 19. Immunol Lett. 2015. PMID: 26096822 Free PMC article. Review. - Trial Watch:: Oncolytic viruses for cancer therapy.
Pol J, Bloy N, Obrist F, Eggermont A, Galon J, Cremer I, Erbs P, Limacher JM, Preville X, Zitvogel L, Kroemer G, Galluzzi L. Pol J, et al. Oncoimmunology. 2014 Jun 1;3:e28694. doi: 10.4161/onci.28694. eCollection 2014. Oncoimmunology. 2014. PMID: 25097804 Free PMC article. Review. - Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.
Nguyen A, Ho L, Wan Y. Nguyen A, et al. Front Oncol. 2014 Jun 11;4:145. doi: 10.3389/fonc.2014.00145. eCollection 2014. Front Oncol. 2014. PMID: 24967214 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous